Feature Oramed sees value creating events through 2016 By Len Zehr Oramed Pharmaceuticals’ (NASDAQ:ORMP) oral insulin development program has multiple value-creating events in the works through 2016. They include completion of an ongoing Phase 2b FDA multi-site study for... December 1, 2015